Updated:
WearLinq
WearLinq Labs received FDA clearance for the eWave, a wireless 6-lead continuous ECG monitor built for diagnostic-grade ambulatory cardiac monitoring.
WearLinq
WearLinq Labs developed the eWave, an FDA-cleared wireless 6-lead ECG monitor purpose-built for continuous ambulatory cardiac monitoring. The device is engineered to be the lightest on the market, a design choice aimed squarely at patient compliance during extended wear protocols. The platform architecture splits into patient-side and clinician-side applications: a Bluetooth-enabled mobile app for personal smartphones and the LiveLinq physician portal, which surfaces the full waveform study for modalities including Extended Holter monitoring. The eWave generates six distinct ECG leads, giving clinicians a multidimensional view of cardiac activity that single-lead patches cannot provide. WearLinq positions the device for clinician-directed remote monitoring with daily STAT report delivery. The LiveLinq portal enables beat-by-beat waveform review, configurable display layouts, and a zoom function for detailed signal-level analysis. The company's regulatory footprint is anchored by its FDA clearance, which covers the eWave as a continuous monitoring device in the United States. The firm operates from San Francisco and has not publicly disclosed team size, funding rounds, or venture backers. As of early 2026, the company continues to market the eWave as the first wireless continuous 6-lead multimodal monitor, with clinical data on file as referenced in its marketing materials. WearLinq's structural distinction lies in focusing on diagnostic-grade continuous monitoring rather than episodic event recording. By combining six-lead signal fidelity with a lightweight patch designed for long-duration wear, the company is targeting the gap between consumer wearables that offer limited lead views and traditional Holter monitors that burden patients with wired electrode configurations. The model depends on clinician adoption of a full-disclosure review workflow, which shifts the diagnostic paradigm from relying on triggered alerts to examining the complete ambulatory recording.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
What regulatory clearance does WearLinq's eWave device hold?
The eWave 6-lead ECG monitor holds FDA clearance as a wireless, continuous, multimodal cardiac monitoring device. The company markets it specifically as the first FDA-cleared wireless continuous 6-lead ECG multimodal monitor. The clearance covers ambulatory monitoring applications including Extended Holter modalities.
How does WearLinq's clinical data platform work?
WearLinq's LiveLinq platform provides clinicians with full-disclosure access to the entire patient ECG study. The system delivers all waveform data — not just triggered episodes — and supports configurable display layouts and a zoom feature for detailed signal-level analysis. The platform is designed for use across all monitoring modalities, including Extended Holter, and generates STAT reports on a daily basis.
What differentiates the eWave from single-lead ECG monitors?
The eWave captures six distinct ECG leads rather than a single lead, which the company states provides six times the diagnostic visibility. This multi-lead configuration gives clinicians a multidimensional view of cardiac activity, enabling more detailed interpretation of rhythm abnormalities and ischemic changes that a single-lead patch would miss. The device is also the lightest ECG monitor on the market, a design factor intended to improve patient compliance during continuous wear.
Where is WearLinq headquartered and in which markets does it operate?
WearLinq is headquartered in San Francisco, California. The company markets its eWave device in the United States, where it holds FDA clearance. The firm has not publicly disclosed international regulatory approvals or commercial operations outside the US market.
What is WearLinq's known funding status?
WearLinq has not publicly disclosed its venture funding history, total capital raised, or institutional investors. The firm operates as a private company and does not list financial backers on its website or in publicly available materials as of early 2026.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: